Lilly 2Q11 2Q Revenues: $6.3 billion (+9%) 2Q Earnings: $1.2 billion (-11%) YTD Revenues: $12.1 billion (+8%) YTD Earnings: $2.3 billion (-13%) Comments: Revenue growth comprised a 5% increase in sales and 4% from the impact of foreign exchange. Zyprexa sales were up 12% to $1.4 billion. Cymbalta sales were $1.0 billion, up 16%. Alimta sales were $613.4 million (+11%). Humalog sales were $586.9 million (+16%). Cialis sales were up 14% to $477.2 million. Humulin sales were up 18% to $311.8 m...